Molycorp's (MCP-11%) ugly day nears a merciful end, capped by a Dahlman Rose downgrade based on the unanticipated additional scaling up of capital requirements, also noting an additional $130M in capex for 2013. Assuming the proposed $300M capital raise is finalized, 25M new shares are issued and the revised capex, the firm sees a negative ~$1.00/share impact to NAV.